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Objective: In the setting of acute pulmonary artery hypertension, techniques 
to reduce right ventricular energy requirements may ameliorate cardiac 
failure and reduce morbidity and mortality. Inhaled nitric oxide, a selective 
pulmonary vasodilator, may be effective in the treatment of pulmonary 
artery hypertension, but its effects on cardiopulmonary interactions are 
poorly understood. Methods: We therefore developed a model of hypoxic 
pulmonary vasoconstriction that mimics the clinical syndrome of acute 
pulmonary hypertension. Inhaled nitric oxide was administered in concen- 
trations of 20, 40, and 80 ppm. Results: During hypoxic pulmonary. 
vasoconstriction, the administration of nitric oxide resulted in a significant 
improvement in pulmonary vascular mechanics and a reduction in right 
ventricular afterload. These improvements were a result of selective 
vasodilation of small pulmonary vessels and more efficient blood flow 
through the pulmonary vascular bed (improved transpulmonary vascular 
efficiency). The right ventricular total power output diminished during the 
inhalation of nitric oxide, indicating a reduction in right ventricular energy 
requirements. The net result of nitric oxide administration was an increase 
in right ventricular efficiency. Conclusion: These data suggest that nitric 
oxide may be beneficial to the failing right ventricle by improving pulmo- 
nary vascular mechanics and right ventricular efficiency. (J Thorac Car- 
diovasc Surg 1997;113:1006-13) 
A lthough arterial hypoxia may increase pulmonary vascular esistance, alveolar hypoxia is probably 
more important in causing hypoxic pulmonary vaso- 
constriction and acute pulmonary artery hyperten- 
sion. 1 Despite an improved understanding of the 
pathophysiologic features of pulmonary artery hy- 
pertension and improvements in diagnosis and sup- 
portive care, morbidity and mortality from pulmo- 
nary artery hypertension remain high. Pulmonary 
artery hypertension can lead to an increase in right 
ventricular (RV) afterload and RV energy require- 
ments, which can subsequently result in acute RV 
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failure and reduced oxygen delivery. In these condi- 
tions, one approach designed to improve RV per- 
formance is to lower RV afterload by decreasing the 
pulmonary artery pressure. 1-3 However, intravenous 
vasodilators directed at reducing the pulmonary 
artery pressure have been shown to be of limited 
value. 1-3 Intravenous vasodilators esult in a nonspe- 
cific vasodilation that can cause systemic hypoten- 
sion and a reduction m cardiac function. 2'3 In 
contrast o intravenous agents, inhaled nitric oxide 
(iNO) has been shown to be a selective pulmonary 
vasodilator. In selected patient populations iNO has 
been shown to reverse hypoxic pulmonary vasocon- 
striction while causing minimal systemic effects. ~-7 
Previous investigations of iNO have focused on 
the ability of iNO to reduce pulmonary artery 
pressure4-6; however, several questions about the 
administration of iNO remain. The precise location 
in the pulmonary vasculature where iNO exerts its 
effects remains uncertain. Discriminating whether 
iNO results in vasodilation of proximal, large pul- 
monary vessels or distal, small vessels, or both. is 
essential in assessing the role of iNO in the various 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 6 
Hillman et aL 10 0 7 
causes of pulmonary artery hypertension. Because 
iNO is delivered to the alveolus, iNO might be more 
likely to exert its effects by physiologically altering 
small, distal vessels. Additionally, how does the RV 
respond to alterations in pulmonary vascular tone as 
a result of iNO administration? If vasodilation of 
the pulmonary vasculature is to be clinically signifi- 
cant, it must reduce RV power requirements and 
increase the efficiency of blood flow through the 
RV-pulmonary system. 
Answers to these questions hould help determine 
which patient populations would benefit from iNO 
therapy. We hypothesized that (1) iNO administra- 
tion would improve pulmonary vascular mechanics 
during hypoxic pulmonary vasoconstriction by vaso- 
dilation of distal, small pulmonary vessels, (2) iNO 
would exert no effects on the proximal, large vessels, 
and (3) the reduction in RV afterload afforded by 
iNO would decrease RV total power requirements 
and increase the efficiency of blood flow through the 
RV-pulmonary system. The purpose of this study 
was, therefore, to determine the precise effects of 
NO during hypoxic pulmonary vasoconstriction on 
pulmonary vascular mechanics, RV performance, 
and the efficiency of blood flow through the RV- 
pulmonary system. By understanding where iNO 
exerts its effects and how iNO alters RV perfor- 
mance one can begin to determine which clinical 
scenarios would most likely benefit from iNO ther- 
apy. 
Material and methods 
The surgical procedures and animal care were per- 
formed in compliance with the guidelines established by 
the National Institutes of Health and the Institutional 
Animal Care and Use Committee of Duke University 
Medical Center. Fourteen swine (15 to 20 kg) were 
premedicated with acepromazine (1.1 mg/kg) and ket- 
amine (22 m~kg). The trachea of each animal was 
orotracheally intubated. Mechanical ventilation was initi- 
ated with a Siemens SV300 ventilator (Siemens, Solno, 
Sweden) in the volume control mode. The inspired oxygen 
fraction (Fio2) was set to achieve an arterial oxygen 
tension (Pao2) greater than 60 mm Hg, and the respira- 
tory rate was adjusted to maintain an arterial carbon 
dioxide tension (Paco2) between 35 and 45 mm Hg. 
Anesthesia was maintained throughout the study with a 
continuous infusion of fentanyl. Intermittent boluses of 
pancuronium were used for neuromuscular blockade. To 
block thromboxane-mediated pulmonary vasoconstric- 
tion, the animals were given an initial intravenous bolus of 
indomethacin (1.4 mg/kg) with a continuous maintenance 
infusion (0.7 mg/kg per hour). Each animal was hepa- 
rinized and continuous heparin infusion was begun to 
prevent clot formation on the intracardiac pressure cath- 
eters. 
A femoral arterial line was placed to continuously 
monitor mean arterial pressure and to obtain arterial 
blood gas samples. After a median sternotomy, the peri- 
cardium was incised and fashioned into a pericardial 
cradle. An ultrasonic flow probe (Transonic Systems Inc., 
Ithaca, N.Y.) was placed around the pulmonary artery at 
the level of the RV outflow tract to measure cardiac 
output. Micromanometer strain gauge pressure catheters 
(Millar Instruments Inc., Houston, Tex.) were introduced 
through subcutaneously tunneled sheaths and placed in 
the pulmonary artery (at the level of the flow probe), RV, 
and left atrium. A fourth pressure catheter was placed 
into an introducer sheath and positioned in the thoracic 
cavity at the level of the left atrium. A chest tube was 
positioned in the thoracic avity, and atrial pacing wires 
were inserted. A fluid-filled pouch was positioned at the 
level of the right atrium-superior vena cava junction and 
connected to a roller pump. This maintained continuous 
cooling of the sinoatrial node to suppress episodes of 
tachycardia. The chest and skin were then closed, all air 
!eaks sealed, and the chest ube placed to water seal. The 
ventilatory rate was adjusted to maintain aPaco2 value of 
35 to 45 mm Hg. A positive end-expirat0ry pressure of 3 
cm H20 was added to prevent alveolar collapse. These 
ventilatory parameters were held constant throughout the 
study. 
Hypoxic pulmonary vasoconstriction. A baseline data 
set was obtained before global hypoxia was induced. 
Global hypoxic pulmonary vasoconstriction was produced 
by administration of an inhaled hypoxic gas mixture. The 
hypoxic gas mixture was obtained by blending nitrogen 
with the inspired gas to achieve a Pao2 value less than 60 
mm Hg (Fio2 16% to 18%) and was titrated to achieve a
50% increase in mean pulmonary artery pressure. The gas 
mixture was maintained constant throughout the remain- 
der of the study period. After the development ofhypoxic 
pulmonary vasoconstriction, the animal's condition was 
allowed to stabilize for 30 minutes. To eliminate heart rate 
effects on calculations of pulmonary impedance and RV 
power indices, the hearts were atrially paced at 150 
beats/min during data acquisition. 
After the development of hypoxic pulmonary vasocon- 
striction, a second data set was obtained. NO (NO 777 
ppm and NO2 <0.1 ppm, National Specialty Gases, 
Durham, N.C.) was then continuously blended into the 
inspiratory circuit of the ventilator. The gas mixture was 
withdrawn from the inspiratory circuit at the level of the 
endotracheal tribe, and NO levels calculated by chemilu- 
minescent analysis (model 42H, Thermo Environmental 
Instruments Inc., Franklin, Mass.). The NO concentration 
was then increased in a nonrandomized sequential fashion 
from 20 ppm to 40 ppm to 80 ppm. The support conditions 
were returned to baseline and measurements repeated. At 
each incremental change of NO the animal's condition 
was permitted to stabilize for 20 minutes before data 
acquisition. 
Measurements and data analysis. Each data set con- 
sisted of 50 seconds of pressure and flow waveforms 
sampled at 500 Hz. Direct measurements included sys- 
temic blood pressure, RV pressure, pulmonary artery 
pressure, left atrial pressure, intrathoracic cavity pressure, 
tracheal pressure, and pulmonary artery blood flow. Ar- 
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Table I. Cardiopulmonary measurements before and during hypoxia 
Pao 2 Ppa CO Rin TVE TP RV dP/dt 
(ram Hg)* (ram Hg)* (ml/min)* (dyne" sec/cmS) * (L/W-min)* (mW)* (mrn Hg/sec)* 
Normoxia 86.0 ± 2.0 15.4 ± 1.3 1313 _+ 86 1034 + 109 25.0 ± 0.2 52.6 _+ 4.9 418 + 23 
Hypoxia 50.9 ± 1.7 22.8 _+ 1.6 1276 _+ 68 1530 -- 154 17.9 ± 1.2 72.5 + 5.8 582 + 57 
Ppa, Pulmonary artery pressure; CO, cardiac output; Rin, pulmonary input resistance; TVE, trauspulmonary vascular efficiency; TP, RV total power. 
*p < 0.05 versus normal ung. 
terial blood ga s measurements were obtained at each 
measurement period. Pao2/Fi02 ratios and oxygen deliv- 
ery (cardiac output × [hemoglobin × arterial Oa satura- 
tion × 1.34] + [Pao 2 × 0.003]) were calculated. 
Pulmonary vascular mechanics and RV performance. 
In addition to pulmonary artery pressure, pulmonary 
measurements included pulmonary input resistance 
[mean pulmonary artery pressure/mean pulmonary blood 
flow) and pulmonary impedance. To calculate the imped- 
ance spectrum, the data sets were individually separated 
into cardiac cycles, and the waveforms were averaged. 8 
Characteristic mpedance, which has been shown to eval- 
uate the large vessels of the proximal pulmonary vascular 
bed, 8 was then derived from the impedance spectrum as 
described later. In contrast, pulmoriary input resistance 
evaluates the entire pulmonary vasculature (proximal and 
distal vessels). 8 To evaluate the effects of iNO on the 
proximal vessels, characteristic impedance was examined. 
To evaluate the distal small vessels, we compared the 
changes that Occurred in characteristic mpedance with 
those that occurred in pulmonary input resistance. For 
example, if iNO administration results in a reduction in 
input resistance with no change in characteristic mped- 
ance, then the reduction in input resistance is related to 
alterations in distal small vessels and not proximal arge 
vessels. 
RV performance was evaluated by calculating RV total 
power, transpulmonary vascular efficiency, and maximal 
RV rate of pressure rise (dP/dt). RV total power was 
obtained from the impedance and flow magnitudes at all 
frequencies (impedance spectrum × pulmonary artery 
blood flow squared) and differentiated into components of
steady power (energy required to move blood forward) 
and oscillatory power (energy wasted to accelerate blood 
in a pulsatile fashion). Maximal RV dP/dt measured by 
the RV pressure catheter was recorded as an index of RV 
chamber contractility. Because this has been shown to be 
sensitive to afterload, the simultaneous measurement of
pulmonary artery pressure was used to interpret this 
index. The final measure of RV performance was 
transpulmonary vascular efficiency, an index we have 
developed in an attempt to quantify the complex relation- 
ship between RV power and pulmonary blood flow. 9-12 
Transpulmonary vascular efficiency was calculated by di- 
viding pulmonary bl0od flow by the power required to 
produce this flow (pulmonary artery blood flow'RV total 
power). 
Baseline hypoxic pulmonary vasoconstriction parame- 
ters were compared between each level of NO adminis- 
tration with a two-way analysis of variance for repeated 
measures. Prehypoxia nd posthypoxia values were com- 
pared in a similar manner. A value of p < 0.05 was 
considered significant. Measurements are reported as 
mean values plus or minus the standard error of the mean. 
Results 
Effects of hypoxic pulmonary vasoconstriction on 
cardiopulmonary interactions. Results from the 14 
animals under conditions of normoxla and global 
hypoxia are summarized in Table I. Animals were 
maintained at an Fio2 between 0.16 and 0.18 to 
achieve hypoxic conditions and pulmonary artery 
hypertension. Mean pulmonary artery pressures in- 
creased by 48% (15.4 ~ 1.3 vs 22.8 T 1.6 mm Hg, 
p - 0.00003) during hypoxia (Table I). Hypoxic 
conditions resulted in a 48% increase in pulmonary 
input resistance (1034 ~- 109 vs 1530 + 154 
dyne.  sec/cm 5. p = 0.004). After the initiation of 
hypoxia, the total power output of the RV increased 
by 37% (52.6 : 4.9 vs 72.5 ~ 5.8 roW. p - 0.006). 
There was a significant increase in maximal RV  
dP/dt (418 ~ 23 vs 582 .: 57 mm Hg/sec, p - 0.01), 
Transpulmonary vascular efficiency decreased by 
28% during hypoxic pulmonary vasoconstriction 
(25.0 + 1.1 vs 17.9 ~- 1.2 L/W-min, p = 0.005), which 
demonstrated less efficient blood flow through the 
RV-pulmonary circuit. During inhalation of the 
hypoxic gas mixture the Pao 2 value decreased 
(86.0 _ 2.0 vs 50.9 ~- 1.7 mm Hg, p - 0.00002) by 
design. 
Effect of iNO on gas exchange. The effects of NO 
on cardiopulmonary measurements are summarized 
in Table II. There was no change in arterial oxygen 
saturation or Pao 2 during inhalation of NO. This 
was as expected inasmuch as a hypoxic gas mixture 
decreases the alveolar Po 2 and decreases the 
amount of oxygen available for gas exchange. Dur- 
ing the study period there was no significant change 
in Paco2. 
Effect of iNO on pulmonary vascular mechanics 
and RV performance. Characteristic impedance re- 
mained constant with the administration of 20 ppm 
of iNO and did not change with increased iNO 
concentrations, which indicated no change in the 
compliance or cross-sectional area of the large 
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Table II. Cardiorespiratoty measurements during NO administration 
0 ppm 20 ppm 40 ppm 80 ppm 0 ppm 
Ppa (mm Hg) 22.8 ± 1.0 19.8 _+ 1.3" 18.9 _+ 1.0" 18.3 ± 0.9* 23.1 ± 1.2 
CO (ml/min) 1276.8 + 67.7 1369.1 ± 87.4 1391.6 _+ 65.6 1357.7 ± 67.7 1266.4 ± 68.9 
Rin (dyne" sec/cm 5) 1530.7 ± 154.2 1230.1 _+ 100.8" 1173.9 _+ 92.1" 1171.2 _+ 95.4* 1538.6 _+ 124.5 
Zo (dyne- sec/cm 5) 149.7 -+ 8.7 139.2 ± 9.3 141.3 + 8.5 145.0 ± 9.5 151.3 _+ 8.8 
TP (roW) 72.5 ± 5.8 71.2 ± 6.9 67.5 +_ 4.8* 64,6 ± 4.6* 71.9 ± 5.3 
SP (mW) 64.0 ± 4.6 60.7 ± 5.9 57.7 _+ 3.9* 54.3 ± 3.8* 63.7 ± 4.7 
OP (mW) 8.5 ± 1.4 10.5 ± 1.8 9.9 ± 1.5 10.2 _+ 1.5 8.2 ± 1.5 
% SP 88.7 ± 1.0 85.4 + 1.7 87.1 _+ 2.2 85.8 ± 2.1 88.6 ± 1.8 
% OP 11.3 _+ 1.0 14.6 +_ 1.7 14.8 ± 1.9 16.9 _+ 1.9 11.4 + 1.8 
TVE (L/W-±in) 17.4 ± 1.3 19.4 _+ 1.2" 20.6 _+_ 1.2" 21.1 ± 1.2" 17.6 _+ 1.2 
RV EDP (ram Hg) 3.9 + 0.7 3.9 ± 0.5 4.1 ± 0.5 4.2 ± 0.4 4.0 ± 0.7 
RV dP/dt (ram Hg/sec) 581.7 ± 56.6 620.2 ± 76.5 603.1 ± 88.2 589.9 -+ 68.8 583.3 _+ 61.3 
MAP (mm Hg) 50.9 ± 4.0 58.9 _+ 4.6 54.3 ± 4.6 54.1 _+ 4.7 52.2 _+ 2.4 
Pao 2 (torr) 50.9 _+ 1.7 49.3 _+ 2.9 49.6 ± 2.6 49.3 ± 2.7 48.8 _+ 4.5 
Do2 (dl/min) 145.3 _+ 8.4 151.6 ± 11.7 154.1 ± 7.8 149.2 ± 6.6 147.7 ± 7.6 
Ppa, Pulmonary artery pressure; CO, cardiac output; Rin, pulmonary input resistance; Zo, characteristic impedance; TP, RV total power; SP, RV steady 
power; OP, RV oscillatory power; TVE, transpulmonary vascular efficiency; EDP, end-diastolic pressure; MAP, mean arterial pressure; DO2, oxygen delivery. 
*p < 0.05 versus 0 ppm. 
pulmonary vessels. During administration of iNO at 
20 ppm, pulmonary artery pressure fell by 13% 
(Table II, Fig. 1). With each incremental increase in 
iNO concentration pulmonary artery pressure was 
further reduced, and the maximal decrease of 20% 
occurred at 80 ppm. However, there were no statis- 
tically significant differences when the various con- 
centrations of iNO were compared. Pulmonary in- 
put resistance fell by 20% during administration of 
20 ppm of NO. The greatest reduction of input 
resistance, 24%, was noted at 40 and 80 ppm. 
Total power generated by the RV decreased 
during iNO administration with a reduction of 11% 
at 80 ppm (Table II, Fig. 2). The components of 
total power include steady and oscillatory power. 
The steady power, or energy produced by the RV to 
move the blood forward, continually diminished 
with each increase in NO concentration, with a 16% 
decrease at 80 ppm. There was no significant change 
in the absolute value of oscillatory power (wasted 
energy to oscillate the blood vessels and energy 
required to overcome inertia), iNO administration 
resulted in a 21% increase in transpulmonary vas- 
cular e~iciency at 80 ppm, indicating more efficient 
blood flow through the RV-pulmonary circuit (Fig. 
3). Preload, as measured by RV end-diastolic pres- 
sure, did not change significantly throughout he 
study (3.9 _+ 0.7 vs 3.9 _+ 0.5 mm Hg, p = 0.83). 
There was no significant change in maximal dP/dt, 
an indicator of myocardial contractility. 
Effect of iNO on systemic circulation and oxygen 
delivery. Systemic pressures did not change signifi- 
cantly at any level of NO concentration studied. 
Because of the study design, there was no significant 
improvement in arterial oxygenation. However, 
there was a trend toward an increase in oxygen 
delivery that was greatest at 40 ppm (145.3 _+ 8.4 vs 
154.1 _+ 7.8 dl/min), but this did not reach statistical 
significance. 
Discussion 
Despite improvements in medical support for 
patients with global hypoxic pulmonary vasocon- 
striction, RV dysfunction continues to be responsi- 
ble for increased morbidity and mortality. Global 
hypoxic pulmonary vasoconstriction is associated 
with an acute elevation of pulmonary artery pres- 
sure and a decrease in RV performance. The in- 
crease in RV total power requirements can result in 
RV dysfunction and subsequent cardiac failure. 1 A 
reduction in RV afterload might improve RV per- 
formance and reduce the likelihood of RV dysfunc- 
tion. 13 The use of intravenous vasodilators to treat 
hypoxic pulmonary vasoconstriction is limited be- 
cause of the severe systemic vasodilation, worsening 
cardiac performance, and diminished ventilation- 
perfusion matching that result. 2' 3 Because iNO se- 
lectively reduces pulmonary artery pressure, iNO 
administration might provide an important hera- 
peutic strategy for patients with hypoxic pulmonary 
vasoconstriction.l-3 
In this study, iNO administration reduced pulmo- 
nary artery pressure by 20% and pulmonary input 
resistance by 24%. These effects resulted in a signif- 
icant reduction in RV total power requirements, an 
increase in transpulmonary vascular efficiency, and 
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Fig. 1. NO resulted in a decrease of pulmonary artery 
(Pa) pressure. *p < 0.05 versus 0 ppm. Pre, Before NO; 
Post, after NO. 
improvement in RV performance. One objective of 
this study was to define more precisely the effects of 
iNO on the pulmonary vasculature. Conventional 
cardiopulmonary physiology is based on "steady- 
flow" hemodynamics. Because pulmonary blood 
flow is pulsatile, conventional steady-flow measure- 
ments do not fully describe cardiopulmonary hemo- 
dynamics. 14 Fourier analysis of pulmonary pressure 
and blood flow separates these measurements into 
steady and pulsatile components, which permits 
quantitative descriptions regarding the physical 
state of the pulmonary vasculature. 15 In contrast o 
pulmonary input resistance, which describes only 
steady-state pressure and flow, characteristic imped- 
ance includes the pulsatile components of blood 
flow in the pulmonary vascular bed. Characteristic 
impedance calculated from the impedance spectrum 
defines the physical state of the pulmonary vascular 
bed. Characteristic impedance varies inversely to 
the compliance and the cross-sectional rea of the 
large pulmonary vessels. As has been demonstrated 
by our data and by others, iNO results in a signifi- 
cant reduction in input resistance. 6' 7 However, in 
our study, characteristic mpedance remained con- 
stant. This demonstrated that the vasodilator prop- 
erties of iNO were effective at the level of the small 
pulmonary vessels with a minimal effect on larger 
pulmonary vessels. Similar results were suggested by 
Celermajer and associates 16 in children with ob- 
structive lesions of the left side of the heart. Seg- 
mental arterial diameter was unchanged uring in- 
~-~ 100 
~ 80  
~.~ ~ 60 
I l l  
~ ~ 40  
20 
0 
Pre 20 40 80 Post 
NO (ppm) 
Fig. 2. Total RV power output diminished uring NO 
administration and reached significance at80 ppm. *p < 
0.05 versus 0 ppm. Pre, Before NO; Post, after NO. 
fusion of Ng-monomethyl-L-arginine (an inhibitor of 
NO synthesis), suggesting the effect of iNO was 
distal to the segmental pulmonary arteries. Similarly 
in our model iNO resulted in relaxation of smooth 
muscle cells that were in close proximity to the 
alveoli with no evidence of vasodilation of the larger 
proximal vessels. These data may be helpful in 
defining which pathophysiologic conditions will re- 
spond to iNO therapy. By identifying the precise 
location where iNO acts, one can begin to under- 
stand why patients with certain pathophysiologic 
conditions benefit from iNO administration whereas 
others do not. Patients with primarily small-vessel 
abnormalities (pulmonary venous hypertension as 
occurs in mitral stenosis, neonates with pulmonary 
artery hypertension, and patients with acute respi- 
ratory distress yndrome) may respond favorably to 
iNO. In these patients, attempts to use iNO to dilate 
small distal vessels may prove beneficial. In contrast, 
patients with a predominant arteriolar abnormality, 
such as occurs in certain patients with primary 
pulmonary" artery hypertension, may not show a 
response to iNO. Further clinical studies appear 
warranted. In these clinical studies, separation of 
patients in whom the pulmonary artery hypertension 
is based on small-vessel abnormalities from those 
with large-vessel abnormalities may provide greater 
insight into the clinical utility of iNO, 
RV performance was evaluated by several tradi- 
tional measurements including cardiac output, RV 
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end-diastolic pressure, and maximal RV dP/dt. Be- 
cause these approaches provide a limited evaluation 
of the RV, we measured RV total power output and 
transpulmonary vascular efficiency. RV total hy- 
draulic power is calculated from the impedance 
spectrum and differentiated into components of 
steady power (energy required to move blood for- 
ward) and oscillatory power (wasted energy to move 
blood in an oscillatory fashion). Increased total 
power results in greater RV energy requirements. 
This is in contrast to RV work, which examines the 
load on the RV alone without regard to time. For 
example, walking up a flight of stairs requires the 
same amount of work as running up the same stairs. 
However, the power output is higher for running 
versus walking because the same amount of work is 
performed in a shorter period. Similarly, a heart hat 
is producing aset amount of work per beat at a slow 
heart rate is generating less power than one produc- 
ing the same work per beat at a high heart rate. By 
evaluating RV total power one can measure the 
energy required to achieve agiven pulmonary blood 
flow. An increase in RV total power may result from 
an increase in RV work or a decrease in the time 
required to perform the work. Provided pulmonary 
blood flow does not change, a decrease in RV total 
power is beneficial because it indicates adecrease in 
the energy required by the RV to produce the given 
pulmonary blood flow. 
Transpulmonary vascular efficiency couples RV 
workload with pulmonary blood flow and describes 
how" efficiently blood flows through the RV-pulmo- 
nary circuit. Conditions that decrease pulmonary 
blood flow and increase RV total power require- 
ments result in a reduction in transpulmonary vas- 
cular efficiency. Therefore, by linking power and 
output, transpulmonary vascular efficiency is a mea- 
sure of RV performance and might indicate trends 
in RV performance not appreciated when power 
and output are evaluated separately. 9 Transpul- 
monary vascular efficiency has been shown to be 
sensitive to small changes in RV performance. 9-1~ 
Transpulmonary vascular efficiency links the 
amount of pulmonary blood flow with the RV power 
requirements necessary to produce this blood flow, 
providing a more precise evaluation of the RV- 
pulmonary system. An increase in transpulmonary 
vascular efficiency indicates ahigher flow for a given 
amount of RV power output and, therefore, a more 
efficient RV-pulmonary system. In contrast, a fall in 
transpulmonary vascular efficiency indicates less 
pulmonary blood flow for a given RV power output 
120-  
"-  100-  
80-  
60-  
40-  
~9. 20-  
Pre 20 40 
f ~  
<%z<,~ 
\ \ xxxx  
\ \ \ \ \ \  
x \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
\ . \ \ \ \ x  
\ \ \ \ \ \  
x",.\\\'q 
\ \ \ \ \ x  
,\\\\',~ 
\ \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
\ \ \ \ \ \  
N \ \ \ \ \  
80 Post 
NO (ppm) 
Fig. 3. NO administration significantly improved trans- 
pulmonary vascular efficiency (TVE) (pulmonary blood 
flow/total RV power). *p < 0.05 versus 0ppm. Pre, Before 
NO; Post, after NO. 
and a fall in efficiency. Transpulmonary vascular 
efficiency has been shown to be a sensitive indicator 
of overall effectiveness of the RV-pulmonary sys- 
tem. 9-11 
When hypoxic pulmonary vasoconstriction was 
created by global hypoxia, RV power increased by 
37% and pulmonary blood flow decreased. There 
was a corresponding decrease in transpulmonary 
vascular efficiency by 24%, indicating less efficient 
blood flow through the pulmonary vessels. When 
iNO was administered during hypoxic pulmonary 
vasoconstriction, total RV power and steady power 
decreased. The reduction in RV power require- 
ments hould be beneficial to the RV by decreasing 
RV myocardial oxygen demand, iNO administration 
also resulted in a 24% increase in transpulmonary 
vascular efficiency as pulmonary blood flow became 
more efficient. Of note is that transpulmonary vas- 
cular efficiency significantly increased at low doses 
of iNO before a significant reduction in RV power. 
It was not until a 40 ppm concentration f iNO was 
administered that RV power significantly decreased. 
Thus transpulmonary vascular efficiency is a sensi- 
tive indicator of RV performance as has been 
suggested in previous tudies. 9q~ One objective of 
iNO therapy is to improve RV performance by 
improving pulmonary vascular mechanics. Our data 
suggest hat in this model of hypoxic pulmonary 
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vasoconstriction, iNO achieves this goal and is ben- 
eficial for the RV. 
The effects of iNO may be more dramatic in 
conditions in which preexisting RV dysfunction is
present. The dysfunctional RV is sensitive to even 
small changes in pulmonary vascular esistance or 
impedance. Our study was an acute model and as 
such the RV was not subject o stress for a long 
period. In clinical conditions in which the RV is 
subjected to stress for a longer period, RV perfor- 
mance might progressively deteriorate. Our data 
might, therefore, underestimate the clinical benefit 
of iNO on RV performance. 
The effect of iNO on left ventricular filling pres- 
sures has been examined in a few clinical stud- 
ies.12, 17, 18 In these studies there was an increase in 
pulmonary capillary pressure. In theory, this might 
be a result of increased left ventricular volume as a 
result of an increase in RV output. Although the 
increase in left ventricular volume may be beneficial 
in conditions in which left ventricular volume is 
limited, it may prove detrimental in conditions in 
which left ventricular volume is excessive. Such 
conditions include those in patients with congestive 
left ventricular dysfunction. In these conditions, 
iNO should be used cautiously and the effects of 
iNO on left ventricular performance monitored. 
There was a trend toward dose-dependent 
changes associated with iNO; however, these 
changes did not reach significance. The effective 
dose of iNO may vary depending on the patho- 
physiologic conditions. In several studies that exam- 
ined the use of iNO in acute respiratory distress 
syndrome, doses as low as 2 to 3 ppm achieved 
beneficial results. 19-21 After operations for con- 
genital heart disease, iNO doses required to pro- 
duce the desired results ranged from 2 ppm to 80 
ppm.6-7, 22-24 These studies indicate that the dose of 
iNO must be individualized for each patient and 
titrated to the lowest dose that achieves the desired 
effects. 
We observed no significant change in the Pa02/ 
Fi02 ratio during the administration of iNO. The 
decreased level of alveolar Po 2 in this model imited 
the amount of oxygen available for gas exchange and 
would not permit an increase in the Pao2/Fi02 ratio. 
Frostell and coworkers 5 noted similar findings in 
healthy adult human volunteers breathing a hypoxic 
gas mixture. In that study, despite a constant Pa02/ 
Fi02 ratio and no improvement in Pa02, systemic 
oxygen delivery improved as a result of increased 
cardiac output during administration f iNO. 
One limitation of this study was the use of an 
animal model to mimic acute pulmonary artery 
hypertension. Swine have been used in previous 
studies of cardiopulmonary interactions. 9-11' 25 Ad- 
ditionally, the cardiac and pulmonary anatomy and 
physiologic features of the swine are similar to those 
of human beings. This model does not examine the 
potential differences that can occur between ew- 
born and older swine. Newborn swine may respond 
differently than older swine because of developmen- 
tal differences. Examination of these developmental 
differences was not a subject of this investigation 
because we sought o characterize the response of 
older animals. 
A second limitation of the study was the nonran- 
domized sequential delivery of NO. Measured if- 
ferences between the iNO levels may be related to 
degradation of the preparation rather than real 
differences between the levels of iNO studied. After 
data collection at 80 ppm of NO, delivery of NO was 
returned to 0 ppm. There were no significant differ- 
ences between measurements made before inhala- 
tion of NO and those made after NO administration 
(Table II). These findings indicate that the mea- 
sured differences were not a result of degradation f
the preparation. 
In summary, we have demonstrated that during 
global hypoxic pulmonary vasoconstriction, iNO im- 
proved pulmonary vascular mechanics by decreasing 
pulmonary artery pressure and input resistance 
through physiologic alterations in small vessels. Ad- 
ditionally, iNO improved RV performance by re- 
ducing RV total power requirements and improving 
transpulmonary vascular efficiency. These data sug- 
gest that iNO therapy is beneficial to the RV and 
should be considered in conditions with RV dys- 
function and hypoxic pulmonary vasoconstriction. 
Further studies of iNO in conditions of RV dysfunc- 
tion with and without hypoxic pulmonary vasocon- 
striction are warranted. 
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